The Benefit of Acarbose in NIDDM Patients with Secondary Failure to Glibenclamide (Manfaat Akarbose pada Pengobatan Diabetes Melitus tidak Tergantung Insulin (DMTTI) Gagal Sekunder Sulfonilurea) | Perpustakaan dan Galeri Kebijakan Kesehatan

Pencarian berdasarkan :

SEMUA Pengarang Subjek ISBN/ISSN Pencarian Spesifik

Pencarian terakhir:

Text

The Benefit of Acarbose in NIDDM Patients with Secondary Failure to Glibenclamide (Manfaat Akarbose pada Pengobatan Diabetes Melitus tidak Tergantung Insulin (DMTTI) Gagal Sekunder Sulfonilurea)

et al - Nama Orang; Sampeliling, A. - Nama Orang;

Arround 10 percent NIDDM patients will develope secondary failure every year. Acarbose could lower the absorbtion of glucose from the intestines. The aim of the study is to evaluate the benefit of acorbose as adjuvant treatment to NIDDM with secondary failure to glibenclamide. Patients were secondary failure to glibenclamide include to the study. The study was done in two phases. First phase: treatment with glibenclamide 15 mg/day for 12 weeks. Second phase: acarbose 2x 100 mg/day were added for the next 12 weeks. At week 0.12 and 14 fasting blood sugar, one hour and two hours post prandial, HbA and serum lipids were examined. Addition of acarbose in NIDDM patients with secondary failure to glibenclamide not only improved the glycemic control but also the fasting insulin level and serum lipid profiles.

Ketersediaan

Belum memasukkan lokasi Belum memasukkan lokasi

A00001190

Tersedia

Informasi Detail

Judul Seri: -
No. Panggil: Majalah Kedokteran Indonesia,46(9)1996:484-488
Penerbit: : ., 1996
Deskripsi Fisik: -
Bahasa
ISBN/ISSN: -
Klasifikasi: -
Tipe Isi: -
Tipe Media: -
Tipe Pembawa: -
Edisi: -
Subjek: diabetes mellitus, non-insulin-dependent
Info Detail Spesifik: -
Pernyataan Tanggungjawab: -

Versi lain/terkait

Tidak tersedia versi lain

Lampiran Berkas

Tidak Ada Data

Komentar

Anda harus masuk sebelum memberikan komentar